Spironolacton as adjunctive treatment of negative symptoms in patients with schizophrenia
Phase 3
Recruiting
- Conditions
- schizophrenia.Paranoid schizophreniaF20.0
- Registration Number
- IRCT20091229002935N8
- Lead Sponsor
- Sanandaj University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 52
Inclusion Criteria
Diagnosis of Schizophrenia based on DSM-5 criteria
Age between 18-55 years old
Chronic Schizophrenia- duration of the disorder more than 2 years
Minimum score of 20 in negative sub score
being stable on antipsychotic for the last 2 months(6 months for clozapine)
Exclusion Criteria
Any serious medical or neurological problem
IQ less than 70.
Substance dependence during the last 6 months(except for nicotine and caffeine)
receiving ECT during the last 2 months
Acute or chronic systemic diseases
History of head trauma
exacerbation of symptoms(developing the active phase)
hypersensitivity to spironolacton
post-psychotic depression
gynecomastia
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-8 after beginning of treatment. Method of measurement: by Positive and Negative Symptoms Scale.
- Secondary Outcome Measures
Name Time Method